Soleno Therapeutics Inc (SLNO) — Capital Reinvestment Ratio
Latest as of March 2026:
0.00x
Soleno Therapeutics Inc (SLNO) has a Capital Reinvestment Ratio of 0.00x as of March 2026, meaning it reinvests 0% of its operating cash flow ($25.98 Million) in capital expenditures ($40.00K). See Soleno Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$25.98 Million
USD
Capital Expenditures
$40.00K
USD
Data as of
Mar 2026
Most recent filing
Soleno Therapeutics Inc Capital Reinvestment Ratio (2025–2025)
This chart tracks Soleno Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Soleno Therapeutics Inc (2025–2025)
Year-by-year Capital Reinvestment Ratio for Soleno Therapeutics Inc from 2025 to 2025. For live market cap and broader valuation context, see Soleno Therapeutics Inc (SLNO) total market value.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | $46.80 Million | $73.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow